Financials Lipidor AB

Equities

LIPI

SE0012558617

Pharmaceuticals

Delayed Nasdaq Stockholm 04:21:06 16/07/2024 pm IST 5-day change 1st Jan Change
0.05 SEK +0.81% Intraday chart for Lipidor AB +6.38% -90.08%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 388.2 355.9 248.8 21.33 14.6
Enterprise Value (EV) 1 361.1 291.6 197.5 12.4 14.5
P/E ratio -24.1 x -20.4 x -11.1 x -0.52 x -1.27 x
Yield - - - - -
Capitalization / Revenue 521 x 571 x 16 x 73 x 168 x
EV / Revenue 485 x 468 x 12.7 x 42.5 x 167 x
EV / EBITDA -26.2 x -18 x -9.28 x -0.3 x -0.97 x
EV / FCF 65.5 x -30.5 x -31.7 x -0.52 x -1.42 x
FCF Yield 1.53% -3.27% -3.15% -194% -70.6%
Price to Book 14.5 x 6.02 x 5.53 x 9.94 x -1.56 x
Nbr of stocks (in thousands) 23,584 26,384 29,977 28,977 28,977
Reference price 2 16.46 13.49 8.300 0.7360 0.5040
Announcement Date 12/05/20 23/04/21 28/04/22 26/04/23 15/05/24
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.243 0.745 0.623 15.6 0.292 0.087
EBITDA 1 -7.599 -13.79 -16.22 -21.27 -41.2 -14.92
EBIT 1 -7.634 -13.81 -16.26 -21.38 -41.47 -15.45
Operating Margin -3,141.56% -1,853.42% -2,610.59% -137.09% -14,202.05% -17,763.22%
Earnings before Tax (EBT) 1 -7.637 -13.81 -16.2 -21.29 -41.38 -11.48
Net income 1 -7.637 -13.81 -16.2 -21.29 -41.38 -11.48
Net margin -3,142.8% -1,853.29% -2,600.96% -136.49% -14,170.89% -13,201.15%
EPS 2 -0.5100 -0.6832 -0.6600 -0.7482 -1.428 -0.3964
Free Cash Flow 1 -15.13 5.511 -9.549 -6.231 -24 -10.23
FCF margin -6,225.57% 739.78% -1,532.74% -39.94% -8,219.09% -11,763.22%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 29/05/19 12/05/20 23/04/21 28/04/22 26/04/23 15/05/24
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1.17 27.1 64.3 51.3 8.93 0.1
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -15.1 5.51 -9.55 -6.23 -24 -10.2
ROE (net income / shareholders' equity) -85.2% -66.9% -35.8% -39.7% -181% 319%
ROA (Net income/ Total Assets) -41.9% -37.1% -21.6% -22.1% -73.4% -105%
Assets 1 18.22 37.18 75.06 96.3 56.39 10.97
Book Value Per Share 2 0.9600 1.140 2.240 1.500 0.0700 -0.3200
Cash Flow per Share 2 0.0800 1.150 2.260 1.770 0.3100 0.0200
Capex - - 0.32 0.77 0.46 -
Capex / Sales - - 50.72% 4.96% 157.19% -
Announcement Date 29/05/19 12/05/20 23/04/21 28/04/22 26/04/23 15/05/24
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

1st Jan change Capi.
-90.08% 1L
+63.05% 86TCr
+40.02% 63TCr
-4.78% 36TCr
+17.52% 32TCr
+8.43% 30TCr
+5.44% 23TCr
+16.50% 23TCr
+14.63% 18TCr
+1.08% 16TCr
Other Pharmaceuticals